Guggenheim Maintains Buy Rating on UroGen Pharma, Lowers Price Target
Guggenheim reaffirmed its 'Buy' rating on UroGen Pharma while adjusting the price target to $56 from $58.
Stocks · News reference
Oppenheimer Analyst Commentary on UroGen Pharma's Zusduri
Oppenheimer provided positive commentary on the growth potential of UroGen Pharma's product, Zusduri, characterizing it as an early-stage opportunity.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56
UroGen Pharma Reports Third Quarter 2026 Financial Results
UroGen Pharma announced its financial results for the third quarter ended September 30, 2026, highlighting $68.0 million in revenue from ZUSDURI.
8-K filing — UroGen Pharma Ltd. (URGN)
Filed: 2026-11-04 AccNo: 0001437749-26-034769 Size: 244 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
UroGen Pharma to Present at Guggenheim Securities 3rd Annual Healthcare Innovation Conference
UroGen Pharma announced that its management team will participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference scheduled for November 9-11, 2026.
UroGen Pharma Announces First Patient Dosed in Phase 1 Trial of UGN-501
UroGen Pharma has initiated a Phase 1 clinical trial for UGN-501, an investigational oncolytic virus therapy for non-muscle invasive bladder cancer, by dosing the first patient.